Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Are Investors Too Bearish on Energy?
03:53 - Evercore ISI Senior Managing Director James West discusses oil and his investment ideas. He speaks on “Market Makers.” (Source: Bloomberg)
  • The Ball Is in Tsipras’ Court: Asimakopoulou
  • What If Greek Banks Don't Open for Two Weeks?
  • Gold Poised to Break Three-Day Losing Streak